X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (48) 48
blasting (45) 45
heating (45) 45
lighting (45) 45
mechanical engineering (45) 45
weapons (45) 45
chemistry (39) 39
index medicus (39) 39
metallurgy (39) 39
physics (35) 35
male (32) 32
middle aged (30) 30
aged (29) 29
oncology (29) 29
compositions based thereon (26) 26
organic macromolecular compounds (26) 26
their preparation or chemical working-up (26) 26
female (24) 24
combustion apparatus (23) 23
combustion processes (23) 23
electricity (23) 23
adult (21) 21
peptides (21) 21
basic electric elements (19) 19
immunotherapy (19) 19
burners (17) 17
cancer vaccines - immunology (17) 17
cancer vaccines - therapeutic use (17) 17
compositions of macromolecular compounds (17) 17
immunology (16) 16
ranges (16) 16
survival (16) 16
ventilating (16) 16
aged, 80 and over (15) 15
antigens (15) 15
cancer vaccines - administration & dosage (15) 15
optics (15) 15
vaccination (15) 15
astronomy & astrophysics (14) 14
details of domestic stoves or ranges, of general application (14) 14
other domestic stoves or ranges (14) 14
performing operations (14) 14
precision medicine (14) 14
transporting (14) 14
treatment outcome (14) 14
cancer vaccines - adverse effects (13) 13
devices or arrangements, the optical operation of which ismodified by changing the optical properties of the medium of thedevices or arrangements for the control of the intensity,colour, phase, polarisation or direction of light, e.g.switching, gating, modulating or demodulating (13) 13
flexible materials not otherwise provided for (13) 13
frequency-changing (13) 13
laundering (13) 13
macromolecular compounds obtained otherwise than by reactionsonly involving unsaturated carbon-to-carbon bonds (13) 13
non-linear optics (13) 13
optical analogue/digital converters (13) 13
optical elements, systems, or apparatus (13) 13
optical logic elements (13) 13
t-lymphocytes, cytotoxic - immunology (13) 13
techniques or procedures for the operation thereof (13) 13
textiles (13) 13
treatment of textiles or the like (13) 13
treatment, not provided for elsewhere in class d06, of fibres, threads, yarns,fabrics, feathers, or fibrous goods made from such materials (13) 13
use of inorganic or non-macromolecular organic substances ascompounding ingredients (13) 13
after-treatment not covered by subclasses c08b, c08c, c08f,c08g (12) 12
animals (12) 12
chemotherapy (12) 12
clinical trials (12) 12
general processes of compounding (12) 12
prognosis (12) 12
vaccines (12) 12
vaccines, subunit - immunology (12) 12
working-up (12) 12
antigens, neoplasm - immunology (11) 11
general tagging of cross-sectional technologies spanning over several sections of the ipc (11) 11
general tagging of new technological developments (11) 11
human necessities (11) 11
peptide vaccine (11) 11
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (11) 11
vaccines, subunit - therapeutic use (11) 11
astrophysics (10) 10
biomarker (10) 10
cancer (10) 10
care and treatment (10) 10
immunoglobulin g (10) 10
technologies or applications for mitigation or adaptation againstclimate change (10) 10
cancer vaccines (9) 9
high energy astrophysical phenomena (9) 9
hygiene (9) 9
measuring (9) 9
medical or veterinary science (9) 9
personalized peptide vaccine (9) 9
testing (9) 9
vaccines, subunit - administration & dosage (9) 9
astrophysics - high energy astrophysical phenomena (8) 8
combustion engines (8) 8
cytotoxic t-lymphocytes (8) 8
electric solid state devices not otherwise provided for (8) 8
hot-gas or combustion-product engine plants (8) 8
immunoglobulin g - immunology (8) 8
immunological evaluation (8) 8
lymphocytes (8) 8
medicine, research & experimental (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Science, ISSN 1347-9032, 09/2017, Volume 108, Issue 9, pp. 1732 - 1738
Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a... 
overall survival | Cancer immunotherapy | immune response | personalized peptide vaccine | hepatocellular carcinoma | SURVIVAL | MEMBRANE ANTIGEN | SORAFENIB | CYTOTOXIC T-LYMPHOCYTES | TRIAL | CANCER-PATIENTS | ONCOLOGY | IMMUNOTHERAPY | SUNITINIB | HEPATITIS-C | EXPRESSION | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Vaccination | Drug Resistance, Neoplasm | Male | Liver Neoplasms - therapy | Antineoplastic Agents - administration & dosage | Liver Neoplasms - mortality | Feasibility Studies | Aged, 80 and over | Adult | Female | Precision Medicine | Cancer Vaccines - administration & dosage | Chemoembolization, Therapeutic | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | T-Lymphocytes, Cytotoxic - physiology | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Vaccines, Subunit - administration & dosage | Sorafenib | Aged | Carcinoma, Hepatocellular - therapy | Medicine, Experimental | Medical research | Care and treatment | Hepatoma | Peptides | Antigens | Immunoglobulin G | Feasibility studies | Clinical trials | Cytotoxicity | Hepatocellular carcinoma | Lymphocytes T | Cancer therapies | Survival | Patients | Proteins | Liver cancer | Chemotherapy | Lymphocytes | Immunotherapy | Prostate cancer | Original
Journal Article
by Kato, Taichi and Imada, Akira and Uemura, Makoto and Nogami, Daisaku and Maehara, Hiroyuki and Ishioka, Ryoko and Baba, Hajime and Matsumoto, Katsura and Iwamatsu, Hidetoshi and Kubota, Kaori and Sugiyasu, Kei and Soejima, Yuichi and Moritani, Yuuki and Ohshima, Tomohito and Ohashi, Hiroyuki and Tanaka, Junpei and Sasada, Mahito and Arai, Akira and Nakajima, Kazuhiro and Kiyota, Seiichiro and Tanabe, Kenji and Imamura, Kazuyoshi and Kunitomi, Nanae and Kunihiro, Kenji and Taguchi, Hiroki and Koizumi, Mitsuo and Yamada, Norimi and Nishi, Yuichi and Kida, Mayumi and Tanaka, Sawa and Ueoka, Rie and Yasui, Hideki and Maruoka, Koichi and Henden, Arne and Oksanen, Arto and Moilanen, Marko and Tikkanen, Petri and Aho, Mika and Monard, Berto and Itoh, Hiroshi and Dubovsky, Pavol A and Kudzej, Igor and Dancikova, Radka and Vanmunster, Tonny and Pietz, Jochen and Bolt, Greg and Boyd, David and Nelson, Peter and Krajci, Thomas and Cook, Lewis M and Torii, Ken’ichi and Starkey, Donn R and Shears, Jeremy and Jensen, Lasse-Teist and Masi, Gianluca and Hynek, Tomáš and Novák, Rudolf and Kocián, Radek and Král, Lukáš and Kučáková, Hana and Kolasa, Marek and Šťastný, Petr and Staels, Bart and Miller, Ian and Sano, Yasuo and Ponthière, Pierre de and Miyashita, Atsushi and Crawford, Tim and Brady, Steve and Santallo, Roland and Richards, Tom and Martin, Brian and Buczynski, Denis and Richmond, Michael and Kern, Jim and Davis, Stacey and Crabtree, Dustin and Beaulieu, Kevin and Davis, Tracy and Aggleton, Matt and Morelle, Etienne and Pavlenko, Elena P and Andreev, Maksim and Baklanov, Alexander and Koppelman, Michael D and Billings, Gary and Urbančok, L’ubomír and Ögmen, Yenal and Heathcote, Bernard and Gomez, Tomas L and Voloshina, Irina and Retter, Alon and Mularczyk, Krzysztof and Złoczewski, Kamil and Olech, Arkadiusz and Kedzierski, Piotr and Pickard, Roger D and Stockdale, Chris and Virtanen, Jani and Morikawa, Koichi and ...
Publications of the Astronomical Society of Japan, ISSN 0004-6264, 12/2009, Volume 61, Issue sp2, pp. S395 - S616
Journal Article
Cancer Science, ISSN 1347-9032, 05/2016, Volume 107, Issue 5, pp. 590 - 600
Journal Article
Cancer Science, ISSN 1347-9032, 10/2015, Volume 106, Issue 10, pp. 1257 - 1263
To develop a peptide vaccine for cancer patients with the HLA‐A26 allele, which is a minor population worldwide, we investigated the immunological responses of... 
Cancer vaccines | cytotoxic T‐Lymphocytes | IgG | peptide vaccines | HLA‐A26 | Cytotoxic T-Lymphocytes | HLA-A26 | Peptide vaccines | CELL LUNG-CANCER | SURVIVAL | cytotoxic T-Lymphocytes | RESPONSES | FEASIBILITY | ONCOLOGY | PHASE-II | HLA-A | Immunoglobulin G - blood | Humans | Middle Aged | Vaccination | Male | Antigens, CD - metabolism | Cancer Vaccines - therapeutic use | Neoplasms - therapy | Vaccines, Subunit - therapeutic use | Neoplasms - genetics | Immunoglobulin G - immunology | Biomarkers, Tumor - metabolism | Female | Vaccines, Subunit - adverse effects | Retrospective Studies | T-Lymphocytes, Cytotoxic - immunology | Antigens, Neoplasm - immunology | CTLA-4 Antigen - metabolism | Programmed Cell Death 1 Receptor - metabolism | Cancer Vaccines - adverse effects | Treatment Outcome | Vaccines, Subunit - immunology | Cancer Vaccines - immunology | HLA-A Antigens - immunology | HLA-A Antigens - genetics | Aged | Receptors, Immunologic - metabolism | Medical research | Care and treatment | Peptides | Immunoglobulin G | T cells | Cancer patients | Colon cancer | Analysis | Pancreatic cancer | Medicine, Experimental | Diagnosis | Antigenic determinants | Laboratories | Lung cancer | Clinical trials | Cytotoxicity | Lymphocytes T | Vaccines | Cancer therapies | Cell surface | Population genetics | Immunology | Lymphocytes | Pancreas | Genotypes | Antigens | Cytokines | Research & development--R&D | Chemotherapy | Alleles | Breast | Histocompatibility antigen HLA | Surface markers | Tumors | Original
Journal Article
Cancer Science, ISSN 1347-9032, 09/2007, Volume 98, Issue 9, pp. 1336 - 1343
Expression of excision repair cross-complementation group 1 (ERCC1), p53, or thioredoxin (TRX) is reported to be correlated with resistance to platinum-based... 
CISPLATIN PLUS GEMCITABINE | ONCOLOGY | PHASE-III | GROWTH | THIOREDOXIN PREVENTS | RANDOMIZED-TRIAL | P53 ALTERATIONS | PROGNOSTIC-SIGNIFICANCE | MESSENGER-RNA LEVELS | ERCC1 EXPRESSION | PACLITAXEL | Lung Neoplasms - drug therapy | Predictive Value of Tests | Endonucleases - genetics | Tumor Suppressor Protein p53 - biosynthesis | Humans | Lung Neoplasms - metabolism | Middle Aged | Neoplasm Recurrence, Local - drug therapy | DNA-Binding Proteins - analysis | Lung Neoplasms - pathology | Male | Neoplasm Recurrence, Local - surgery | Tumor Suppressor Protein p53 - genetics | Neoplasm Recurrence, Local - pathology | Platinum Compounds - therapeutic use | Adult | Female | Retrospective Studies | Intracellular Signaling Peptides and Proteins - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - surgery | Neoplasm Recurrence, Local - metabolism | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - metabolism | Endonucleases - biosynthesis | DNA-Binding Proteins - genetics | Membrane Proteins | Disease-Free Survival | DNA Repair | Lung Neoplasms - surgery | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Endonucleases - analysis | DNA-Binding Proteins - biosynthesis | Biomarkers, Tumor - biosynthesis | Medical research | Chemotherapy | Prognosis | Patient outcomes | Medicine, Experimental | Respiratory tract diseases | Development and progression | Lung cancer, Non-small cell | Cancer
Journal Article
BMC cancer, ISSN 1471-2407, 12/2013, Volume 13, Issue 1, p. 613
Journal Article
Cancer Science, ISSN 1347-9032, 04/2017, Volume 108, Issue 4, pp. 598 - 603
Journal Article